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Autophagy is a catabolic process widely conserved among eukaryotes that permits the rapid degradation
of unwanted proteins and organelles through the lysosomal pathway. The Serine/threonine protein ki-
nase ULK2 (unc-51 like kinase 2) plays an important regulatory role in autophagy thanks to its
involvement in mTOR-regulated-initiation and downstream ATG protein-related progression of this
catabolic process. An increasing number of miRNAs have been found to modulate autophagy by targeting
some ATG genes. In this study, we focus on the role of mir-26b in autophagy in prostate cancer (PCa)
cells. We found that miR-26b inhibited autophagy in PC-3 and C4-2 cells, through down-regulation of
ULK2 expression. Dual luciferase reporter assays showed that miR-26b binds the 30UTR of ULK2, sug-
gesting that ULK2 is a direct target of miR-26b. Real-time PCR and Western blot analysis conﬁrmed that
over-expression of miR-26b reduced ULK2 mRNA and protein levels. Our results showed also that miR-
26b was down-regulated in LNCaP, DU145, C4-2 and PC-3 cells compared to the two normal prostate cells
RWPE-1 and WPMY-1 except DU145 cells. This inversely correlates with ULK2 level in the same cell lines.
Expression level of ULK2 in tissues microarray (TMA) of prostate cancer derived from 96 patients
positively correlated with the pathologic stage of the patients (*P < 0.05). Over-expression of ULK2
signiﬁcantly reversed miR-26b-mediated autophagy inhibition. Taken together, our ﬁndings indicate that
mir-26b inhibits autophagy through targeting ULK2 which is up-regulated in PCa.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Autophagy is a cellular degradation pathway in response to
stress such as starvation, growth factor deprivation to maintain
homeostasis whereby cytoplasmic components including proteins
and organelles are engulfed, digested and recycled to sustain
cellular metabolism [1,2]. Moreover, autophagy is a pathway used
for the elimination of pathogens [3] and engulfment of apoptotic
cells [4]. In cancer cells, metabolic stress robustly induces auto-
phagy, which is sustained when apoptosis is blocked [5]. Thea, prostate cancer; miRNAs,
tive; W-mChþ, wasabi-nega-
ine; TMA, tissues microarray.
Lei), whuang0210@163.com
Inc. This is an open access article uabnormal regulation of autophagy has been proved to be related
with cancer, neurodegenerative and other human diseases. How-
ever, the relationship between autophagy and tumor remains
controversial [6].
micro-RNAs (miRs), a subclass of regulatory RNAs (18e22 nu-
cleotides), have recently emerged as potential targets for anti-
cancer therapy, as they target about 80% of protein-coding
mRNAs and regulate multiple cellular pathways [7]. Through
binding the 30UTR of the target mRNA, miRNA down-regulates its
target gene in most cases, and affects cell proliferation [8],
apoptosis [9], cell cycle distribution [10] and autophagy [11]. It has
been widely reported that deregulated miRNA expression is a
common feature of human diseases, especially cancer. Previous
studies have demonstrated that several miRNAs are deregulated in
prostate cancer tissues or cell lines, and miRNAs deregulation is
associated with prostate cancer progression and disease outcome
[12,13].
Nowadays, an increasing number of miRNAs, such as miR-17
[14], and miR-372 [11] have been found to modulate autophagy
by targeting ATG7 and SQSTM1 respectively in human cancer. miR-nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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received much attention from researchers [15,16]; its expression is
frequently abnormal in tumors, suggesting that it may play a sig-
niﬁcant role in cancer [17,18]. In our previous computational anal-
ysis, ULK2 gene was predicted to be regulated by miR-26b. Like
ULK1, ULK2 participates in autophagy regulation. After dephos-
phorylation at ser1027, ULK2 interacts with Atg13 and FIP200 to
activate downstream ATG-related proteins which are essential for
many steps in the autophagy pathway [19].
In this study, we investigated the effects of miR-26b in auto-
phagy on PCa cells and demonstrated that ULK2 relied to the
autophagy is highly expressed in PCa cells and tissues. Here, we
report that ULK2 is down-regulated by miR-26b. miR-26b/ULK2
regulation may have a modulatory effect on autophagy in PCa cells.
2. Materials and methods
2.1. Reagents
LC3B (L7543) antibody, Rapamycin (IPA1021), Chloroquine
(C6628-25G), Polybrene (H9268) were from Sigma. ULK2 (sc-
10907) antibody and ImmunoCruz goat ABC Staining System (sc-
2023) were from Santa Cruz Biotechnology. Goat Anti-Rabbit IgG,
Goat Anti-Mouse IgG, Donky Anti-Goat IgG and BCA protein assay
kits were from CoWin Biotechnology (Beijing, China). b-actin was
from Beyotime Biotechnology (Beijing, China). RNAiso Plus Reagent,
cDNA Reverse Transcription Kits, SYBR® PrimeScript™ RT-PCR Kit II,
RNAiso for Small RNA, SYBR® PrimeScript™miRNA RT-PCR Kits and
restriction enzymes were from TaKaRa (Dalian, China). Lipofect-
amine™ LTX with Plus™ Reagent was from Life Technology. Dual-
Luciferase Reporter Assay System (E1910) were from Promega
(Madison, USA). Puromycin Dihydrochloride (J593) was from
Amersco (USA).
2.2. MicroRNAs and DNA plasmid construction
A microRNA mimicking miR-26b-5p and a non-speciﬁc micro-
RNA (miR-NC) were from Gene Pharma (Shanghai, China). ULK2
over-expression plasmid (31,966) was purchased from Addgene
(USA). The sequences of the wild-type and mutant seed regions of
the ULK2 30UTR were cloned in XhoI-NotI-digested psiCHECKTM-2
Vector (Promega). The mutant ULK2 30UTR sequence was prepared
bymutating ﬁve (5) nucleotides in the seed region for miR-26b. The
sequences of the synthesized oligos were as follows: ULK2 30UTR-
wt forward: 50-GCCTTTGGGATTACAGCTTGAGT-30, reverse 50-
TAGTTCCTGACTTTAGGCCAATC-30; ULK2 30UTR-mut-site1 forward:
50-TATGTATTGTATACATAGACCCTTTCCAGA-30, reverse 50-AAAA-
TATTTTAAACAAGTCCATTGT-30; ULK2 30UTR-mut-site2 forward: 50-
TATGTAATAAACCATTCACCAATTTTAATC-30, reverse 50-ATTCAAG-
CAGGTAAGTAAAAGAAAC-3.
2.3. Cell culture and transfection
Human prostate cancer cell lines LNCaP, DU145, C4-2 and PC-3
were purchased from the China Institute of Basic Medicine,
Peking Union Medical. The normal prostate epithelial cell line
RWPE-1 and Human prostatic stromal myoﬁbroblast cell line
WPMY-1 were purchased from the China center for type culture
collection, Wuhan University. LNCaP, DU145, C4-2 and PC-3 cells
were cultured in RPMI1640medium. RWPE-1 cells were cultured in
Deﬁned Keratinocyte-SFM (GIBCO, Grand Island, NY, USA). WPMY-
1 cells were cultured in DMEM medium. RPMI1640 and DMEM
mediumwere supplemented with 10% fetal bovine serum (Thermo
Scientiﬁc) and penicillin/streptomycin. Deﬁned Keratinocyte-SFM
medium was supplemented only with penicillin/streptomycin.Cells were incubated at 37 C with 5% CO2. For transient trans-
fection, Lipofectamine reagent (Life Technologies, Grand Island, NY,
USA) was used according to the manufacturer's protocol.2.4. Quantitative real-time PCR
PC-3 and C4-2 cells were plated in 6-well plates and transfected
with 100 pmol of miR-26b for 48 h. Total RNA was isolated using
RNAiso Plus Reagent according to the manufacturer's instructions.
500 ng of total RNA was reverse transcribed to cDNA using High-
Capacity cDNA Reverse Transcription Kits (RR036A, TaKaRa). Real-
time PCR were performed on a Bio-Rad CFX 96 Real-time PCR
system using SYBR® PrimeScript™ RT-PCR Kit II (RR820A, TaKaRa)
and ULK2-speciﬁc primers (forward 50-GCCA-
GAAAACTGATTGGGAGGTAGC-30; reverse 50-ATCGTGTCTTCACTGA-
GAGTCCCTT-30). For miR-26b analysis, reverse transcription and
PCRwere carried out using a Bulge-Loop TMmiRNA qPCR Primer Set
for miR-26b-5p and U6 snRNA (RiboBio, China) according to the
manufacturer's instructions. The relative expression levels of ULK2
and miR-26b were respectively normalized to b-actin and U6.2.5. Luciferase assay
PC-3 and C4-2 cells were plated in 24-well plates and cultured
until attachment, then co-transfected with 50 pmol of miR-26b and
50 ng of psiCHECKTM-2-ULK2 30UTR or psiCHECKTM-2-ULK2 30UTR
mutant plasmids. Cells were harvested 48 h after transfection, and
luciferase activities were analyzed by the Dual-Luciferase Reporter
Assay System (Promega, Madison, USA) according to the manu-
facturer's instructions.2.6. mCherry-Wasabi ﬂuorescence microscopy
To generate the mCherry-Wasabi-LC3B cell line, supernatant
containing lentivirus packaged with mCherry-Wasabi-LC3B was
obtained fromGenechem Company and added to cultured PC-3 and
C4-2 cells. The infection was supplemented with Polybrene at a
ﬁnal concentration of 8 mg/ml. The efﬁciency of infection was
analyzed 48 h later by adding Puromycin for another 48 h. Cells
stably expressing mCherry-Wasabi-LC3B were plated in glass-
bottomed cell culture dishes at a density of 1  105 cells/dish and
transfected according to the experiment with miR-26b or ULK2
plasmid together with miR-26b. 48 h post transfection, the cells
werewashed with PBS three times and examined under a Nikon A1
confocal microscope system (Nikon, Japan). Images were treated
with NIS Element Viewer software (Nikon). The average number of
LC3B puncta in each cell was calculated to quantify autophagy ac-
tivity. About 20 cells in each group were used to quantify the LC3B
puncta.2.7. Western blot analysis
Cells were collected after treatment and lysed with lysis buffer
(50 mM TriseHCl pH 7.5, 5 mM EDTA, 0.1% NP-40, 300 mM NaCl,
0.5 mM phenylmethylsulfonyl ﬂuoride and 1  Roche protease
inhibitor cocktail solution). After incubation on ice for 30 min, ly-
sates were cleared by centrifugation at 14,000 g for 15 min at 4 C
and the protein concentrations were determined using BCA protein
assay kits CoWin Biotechnology (Beijing, China). Proteins were
subjected to SDS-PAGE followed by Western blotting. Protein blots
were probed with the indicated primary antibodies and appro-
priate secondary antibodies and protein bands were visualized
using ChemiDoc XRS þ imaging system (Bio-Rad, USA).
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The tissues microarray of prostate cancer utilized in this study
were obtained from Biomax (#PR1921, US). The slide consists of 80
prostate cancer tissues, 8 prostate adjacent tissues and 8 normal
tissues, each sample has a duplicate. IHC is performed by Alena
Biotechnology Ltd.Co (Xi'an, China). ULK2 (sc-10907) antibody and
ImmunoCruz goat ABC Staining System (sc-2023) were used for IHC
staining according to the ABC Staining System protocol. The stain-
ing of tissue scores from 0 (negative) to 3 (positive) combining with
the intensity of staining and percentage of positive stained cells.
KruskaleWallis test was used to establish the difference between
the groups.
2.9. Statistical analysis
Results are expressed as the mean ± SD. The t-test and u-test
were applied to evaluate the differences between groups. For all
tests, results were considered signiﬁcant at P < 0.05.
3. Results
3.1. miR-26b inhibits autophagy in PCa cells
In order to investigate the potential involvement of miR-26b in
autophagy, we stably transfected PC-3 and C4-2 cells with
mCherry-Wasabi-LC3B plasmid using lentivirus. This reporter al-
lows us to distinguish autophagosomes from autophagolysosomes
in cells because the pH-sensitive Wasabi ﬂuorophore is inactive in
acidic autophagolysosomes. Wasabi-positive mCherry-positive
(WþmChþ) puncta are autophagosomes and Wasabi-negative
mCherry positive (W-mChþ) puncta are autophagolysosomes. The
stable PC-3 and C4-2 cell line were transfected with miR-26b or
control miR-NC for 48 h, then imaged with a confocal microscope.
We also used Western blotting to examine the expression ofFig. 1. miR-26b inhibits autophagy in PCa cells. (A, B) PC-3 and C4-2 cells lines stably exp
were acquired with a confocal microscope after 48 h. The graph shows the number of W
mCherry positive (W-mChþ) autophagolysosomes. Scale bar: 10 mm (C, D) PC-3 and C4-2
autophagy activator (Rapa) or an autophagy inhibitor (CQ) for another 24 h. Cell lysates we
internal control.microtubule-associated protein light chain 3 (LC3), which is widely
used to monitor autophagy. Fig. 1A and B shows that the number of
autophagosomes and autophagolysosomes were lower after miR-
26b treatment than miR-NC treatment. To further conﬁrm the in-
hibition of autophagy bymiR-26b, the autophagy ﬂuxwas analyzed
in the presence of Rapamycin; an activator of autophagy and
Chloroquine; an inhibitor of autophagy. As shown in Fig.1C, the
miR-26b-transfected Rapamycin-treated cells accumulated more
LC3-II than the DMSO-treated control cells. More importantly, the
LC3-II band was diminished after cells were consecutively trans-
fected with miR-26b and treated with Chloroquine (Fig. 1D). The
autophagy ﬂux assay shows that miR-26b can repress the conver-
sion of LC3-I to LC3-II.
Taken together, our data suggest that miR-26b efﬁciently in-
hibits autophagy in PC-3 and C4-2 cells.3.2. miR-26b targets ULK2 in PCa cells
Having shown that miR-26b inhibits autophagy in PC-3 and C4-
2 cells, we were interested to ﬁnd out by which mechanism it
operates. We therefore performed miR-26b target prediction in
silico using PicTar, miRanda, and Target Scan, and then selected the
top candidates from the overlapping results generated by the 3
programs. Among the shortlisted candidates, the autophagy-
related gene ULK2 showed two well-conserved miR-26b binding
sites with high binding scores in its 30UTR (starting at positions 656
and 1204); therefore we selected ULK2 for further validation. The
alignment of miR-26b with its putative target sequences in the
human ULK2 30-UTR is depicted in Fig.2A.
In order to investigate whether miR-26b could regulate ULK2 in
prostate cancer cells as predicted by computational analysis, we
constructed a wild-type luciferase reporter vector psiCHECK™2-
ULK2 30-UTR-wt and psiCHECKTM2-ULK2 30-UTR-mut. Co-
transfection experiments showed that miR-26b decreased the
luciferase activity of psiCHECK™2-ULK2 30UTR-wt in PC-3 and C4-ressing mCherry-Wasabi-LC3B was transfected with miR-26b or miR-NC and images
asabi-positive mCherry-positive (WþmChþ) autophagosomes and Wasabi-negative
cells were transfected with miR-26b or miR-NC for 24 h, and then treated with an
re then examined for LC3-I and II expression by Western blot. b-actin was used as an
Fig. 2. miR-26b targets ULK2 in PCa cells. (A) Prediction of miR-26b targets was done in silico and ULK2 was selected as one of the top candidates. The bottom line shows the
mutations introduced into the two putative miR-26b binding sites. (B) PC-3 and C4-2 cells were transfected with psiCHECK-2 vector containing either the wt ULK2-30UTR or the mt
ULK2-30 UTR together with miR-26b or miR-NC for 48 h. The activity of Renilla luciferase was normalized to that of ﬁreﬂy luciferase. (C, D) PC-3 and C4-2 cells were transfected with
miR-26b or miR-NC for 48 h. Total RNA and lysates were subjected to qRT-PCR and Western blot analysis respectively. b-actin was used as an internal control.
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30-UTR-mut, indicating that ULK2 is a direct target of miR-26b.
To further conﬁrm that miR-26b down-regulates ULK2 expres-
sion, PC-3 and C4-2 cells were treated with miR-26b or miR-NC for
48 h. Total RNA and cells lysates were obtained and submitted to
qRT-PCR and western blot. As shown in Fig. 2C and D, treatment of
PC-3 and C4-2 cells with miR-26b signiﬁcantly decreased the ULK2
mRNA and protein levels as compared to the miReNCetreated
cells.
Taken together, miR-26b down-regulates ULK2 expression in
PCa cells.3.3. Expression level of miR-26b and ULK2 in PCa cells
To address whether the miR-26b-dependent inhibition of
autophagy relies on ULK2, we analyzed the expression levels of
miR-26b and ULK2 by qRT-PCR. miR-26b was expressed at a lower
level in prostate cancer cells LNCaP, DU145, C4-2 and PC-3
compared to two normal prostate cells RWPE-1 and WPMY-1,
whereas ULK2 was expressed at a higher level in the same cell
lines except DU145. Western blotting showed also that the ULK2
protein level was higher in LNCaP, C4-2 and PC-3 cells than in
RWPE-1 and WPMY-1 cells (Fig. 3A). We next performed immu-
nohistochemistry (IHC) analysis on TMA of prostate cancer with
speciﬁc ULK2 antibodies. As shown in Fig. 3B, the expression level
of ULK2 was signiﬁcantly higher in prostate cancer tissue than in
the adjacent normal prostate tissue. miR-26b expression is
inversely correlated with ULK2 expression, which suggests that
miR-26b may negatively regulate ULK2 in PCa.3.4. Over-expression of ULK2 rescues miR-26b-mediated autophagy
inhibition
Since miR-26b inhibits the expression of ULK2, we decided to
investigate whether this inhibition contributes to autophagy
regulation in prostate cancer cells. We analyzed the expression
levels of the autophagy markers LC3-I and LC3-II after over-
expression of ULK2 in PC-3 and C4-2 cells followed by treatment
with miR-26b. As shown in Fig. 4A and B, the LC3-I and II protein
levels were higher in the ULK2 over-expression cells than in the
control. We also cotransfected the stable mCherry-Wasabi-LC3B
PC-3 and C4-2 cells with ULK2 and miR-26b or their respective
controls. Fig. 4C and D shows that over-expression of ULK2 signif-
icantly increases the number of autophagosomes and autophago-
lysosomes following the treatment with miR-26b. The graph shows
the number of Wasabi-positive mCherry-positive (WþmChþ)
autophagosomes and Wasabi-negative mCherry positive
(W-mChþ) autophagolysosomes. ULK2 over-expression rescued the
decline in autophagy caused by miR-26b; this supports again the
hypothesis that miR-26b inhibits autophagy by targeting ULK2.4. Discussion
miR-26b has recently received much attention from researchers
because of its inhibitory effects in cancer cells [20e22]. In this study
we evaluated the relationship between miR-26b and autophagy in
prostate cancer cells.
Our ﬁndings demonstrated that miR-26b down-regulates
ULK2 expression and inhibits autophagy in PC-3 and C4-2 cells.
Fig. 3. Expression level of miR-26b and ULK2 in PCa cells and tissues. (A). Total RNA was obtained from RWPE-1, WPMY-1, LNCaP, DU145, C4-2 and PC-3 cells, then miR-26b and
ULK2 expression levels were analyzed by RT-qPCR. The graph shows the ULK2 mRNA and miR-26b levels relative to the two normal cells line RWPE-1 and WPMY-1. ULK2 protein
level was also analyzed by western blot in the same cells. (B). ULK2 expression level was examined by IHC staining analysis in TMA of prostate cancer derived from 96 patients. (C). A
representative example of IHC observed in adjacent normal prostate tissue and prostate cancer tissue using donkey anti-ULK2 antibody were presented. KruskaleWallis test was
used to evaluate the difference between the groups (P < 0.05). b-actin and U6 was used as an internal control.
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higher in prostate cancer cells LNCaP, C4-2 and PC-3, than in the
normal prostate cells RWPE-1 and WPMY-1. The tissues micro-
array (TMA) derived from 96 patients showed that ULK2 is
signiﬁcantly over-expressed in prostate tissues as compared to
the adjacent normal tissues (Fig. 3B). Conversely, miR-26b was
expressed at a lower level in PC-3, C4-2, DU145 and LNCaP cells
compared to RWPE-1 and WPMY-1 cells. Consistent with our
results, down regulation of miR-26b was also reported in other
human cancers, including breast cancer [21,23], lung cancer
[24,25], and colorectal cancer [26,27] suggesting a potential role
for miR-26b in tumor.
Up-regulation of miR-26b inhibits autophagy, these results
were conﬁrmed by Western blot and confocal microscopy anal-
ysis of LC3-I and II (Fig. 1). We further conﬁrmed the role of miR-
26b in that process by using both activator and inhibitor of
autophagy. Rapamycin is known to activate autophagy initiation
by targeting mTOR [28]. Treatment of PC-3 and C4-2 cells with
miR-26b and the autophagy activator Rapamycin resulted in
lower levels of LC3-II, thereby further demonstrating that miR-
26b inhibits autophagy (Fig.1C). miR-26b and Chloroquine
treatment induced the down-regulation of LC3-II (Fig. 1D).Chloroquine suppresses autophagy ﬂux by blocking fusion of
autophagosomes with lysosomes which is considered to be the
last step in autophagy degradation [29].
According to Shin Lee et al., ULK2 interacts with Atg13 and
FIP200 to activate autophagy [30], however its post-transcriptional
regulation remains unclear. We constructed psiCHECK2-ULK2,
psiCHECK2-ULK2-mut plasmids and investigate the effect of miR-
26b on ULK2. A combination of bioinformatics and dual-luciferase
reporter assays identiﬁed ULK2 as a direct target of miR-26b
(Fig. 2A and B). miR-26b is able to down-regulate ULK2 expres-
sion at both mRNA and protein levels in prostate cancer cells PC-3
and C4-2 (Fig. 2C and D). We last up-regulated ULK2 and demon-
strated that over-expression of ULK2 signiﬁcantly rescued miR-
26b-mediated autophagy inhibition in PC-3 and C4-2 cells
(Fig. 4A, B and 4C). This result again showed the role of ULK2 in the
autophagy pathway; it also demonstrated that ULK2 is directly
targeted by miR-26b.
In summary, we found that ULK2 is up-regulated in PCa cells and
tissues. miR-26b inhibits autophagy in part via down-regulation of
ULK2 expression. miR-26b/ULK2 regulationmay have amodulatory
effect in prostate cancer cells.
Fig. 4. Over-expression of ULK2 rescues miR-26b-mediated autophagy inhibition (A, B) PC-3 and C4-2 cells were transfected with ULK2 plasmid or control pcDNA3 together with
miR-26b or miR-NC for 48 h. Cell lysates were then analyzed by Western blot for LC3-I and II. (C, D) Confocal microscope images of a stable mCherry-Wasabi-LC3B-expressing PC-3
and C4-2 cells line after transfection with ULK2 or control pcDNA3 together with miR-26b or miR-NC. Scale bar: 10 mm b-actin was used as an internal control.
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